Phase 2 Stomach Cancer Trial, Recruiting NCT07325630 Sponsor: Zhejiang Cancer Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT07325630
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have signed a consent form agreeing to join the study
  • You are between 18 and 75 years old
  • You have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a tissue test
  • Your cancer cells have tested negative for a specific protein marker called MHC-II (confirm with trial site)
  • Your cancer has been assessed by scans and/or keyhole surgery as being at a certain stage — it has grown into surrounding tissue and spread to nearby lymph nodes, but not to distant parts of the body (confirm with trial site)
  • You have not received any previous treatment for this cancer, such as surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy
  • You are planned to have surgery after completing the pre-surgery treatment used in this trial
  • You are able to swallow tablets
  • You are generally well enough to carry out light daily activities (your doctor will assess this)
  • You are expected to live for at least 6 months

Who may not be able to join:

  • You are pregnant, breastfeeding, or planning to become pregnant within 6 months before, during, or after the last dose of the trial treatment
  • You have signs of active bleeding from your tumour or a related area
  • Your cancer has been identified as having a specific genetic feature called dMMR or MSI-H (confirm with trial site)
  • You have a blockage or near-blockage in your food pipe or the lower part of your stomach that affects eating, digestion, or your ability to swallow tablets
  • You still have side effects from a previous cancer treatment that have not fully resolved, with some exceptions (confirm with trial site)
  • You have a known deficiency of an enzyme called DPD, or you have previously had a severe mouth or gut reaction to a fluorouracil-based chemotherapy drug
  • You have had a severe allergic reaction to any antibody-based medicine or to the chemotherapy drugs used in this trial (capecitabine or oxaliplatin)
  • You have a history of epileptic seizures, or have untreated or active cancer spread to the brain or spinal cord
  • You have a significant heart or blood vessel condition (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13968032995

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
3 November 2025
Est. completion
30 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological Complete Response (pCR) rate of ITT population

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov